74 related articles for article (PubMed ID: 16823497)
21. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Barnett A
Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
[TBL] [Abstract][Full Text] [Related]
22. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
Panina G
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
[TBL] [Abstract][Full Text] [Related]
23. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Ahrén B
Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
[No Abstract] [Full Text] [Related]
24. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.
Ahrén B; Winzell MS; Wierup N; Sundler F; Burkey B; Hughes TE
Regul Pept; 2007 Oct; 143(1-3):97-103. PubMed ID: 17482289
[TBL] [Abstract][Full Text] [Related]
25. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA; Stein PP; Thornberry NA; Wagner JA
Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
[TBL] [Abstract][Full Text] [Related]
26. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats.
Lu SS; Yu YL; Zhu HJ; Liu XD; Liu L; Liu YW; Wang P; Xie L; Wang GJ
J Endocrinol; 2009 Feb; 200(2):159-65. PubMed ID: 18996945
[TBL] [Abstract][Full Text] [Related]
27. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
[TBL] [Abstract][Full Text] [Related]
28. Effects of hypoglycemic agents on patients with diabetes.
Yudkin JS; Smits P
Circulation; 1997 Nov; 96(10):3797-8. PubMed ID: 9396501
[No Abstract] [Full Text] [Related]
29. A facile method for the synthesis of 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid and it's optimization.
Wang HF; Gan R; Zhou J; Liao Q; Wang TB; Zhong CL; Xiang YY; Lin HB; Hu XN
Pak J Pharm Sci; 2018 Jul; 31(4):1393-1397. PubMed ID: 30033425
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular and Hematological Medicine in 2018 - Advances and Insights.
Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):2. PubMed ID: 30215326
[No Abstract] [Full Text] [Related]
31. Pharmacokinetic/pharmacodynamic properties and efficacy/safety of U-500R from randomized clinical studies.
Brusko CS; Taylor AD; Jackson JA
Postgrad Med; 2016 Sep; 128(7):684-5. PubMed ID: 27459686
[No Abstract] [Full Text] [Related]
32. Response to: 'Pharmacokinetic/pharmacodynamic properties and efficacy/safety of U-500R from randomized clinical studies'.
Barnosky A; Shah L; Meah F; Emanuele N; Emanuele MA; Mazhari A
Postgrad Med; 2016 Sep; 128(7):686. PubMed ID: 27452002
[No Abstract] [Full Text] [Related]
33. Molecule of the month. AN-1792.
Drug News Perspect; 2001 Oct; 14(8):490. PubMed ID: 12806433
[No Abstract] [Full Text] [Related]
34. Molecule of the Month.
Drug News Perspect; 2002 Apr; 15(3):186. PubMed ID: 12677262
[No Abstract] [Full Text] [Related]
35. Molecule of the Month.
Drug News Perspect; 2002 Dec; 15(10):674. PubMed ID: 12677252
[No Abstract] [Full Text] [Related]
36. Molecule of the Month.
Drug News Perspect; 2002 Jan; 15(1):59. PubMed ID: 12677244
[No Abstract] [Full Text] [Related]
37. Molecule of the Month.
Drug News Perspect; 2002 Jul; 15(6):371. PubMed ID: 12677234
[No Abstract] [Full Text] [Related]
38. Molecule of the Month.
Drug News Perspect; 2002 Mar; 15(2):120. PubMed ID: 12677219
[No Abstract] [Full Text] [Related]
39. Molecule of the Month.
Drug News Perspect; 2002 May; 15(4):248. PubMed ID: 12677208
[No Abstract] [Full Text] [Related]
40. Molecule of the Month.
Drug News Perspect; 2002 Nov; 15(9):600. PubMed ID: 12677200
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
